Grant: Idea to Innovation
McMaster University
$125,000.00
Optimization and validation of a sol-gel based microarray platform for high-throughput screening
FY 2008-09
Summary
An emerging method for performing bioassays is to print hundreds or even thousands of different proteins on a single microscope slide as micron-sized spots in an ordered pattern (a microarray), and to then expose the proteins to an analyte solution that can simultaneously react with several proteins on the array. Proteins that react with the analyte solution can then be stained with a fluorescent dye, and a pattern of response from the array can be visualized to determine the biological activity of the analytes. Over the past 3 years our group has been developing a new type of protein microarray that is based on the entrapment of proteins into a silica-based polymer, which is then printed as an array. This has allowed us to develop a highly parallel fluorescence-based small molecule screening technology for simultaneous assaying of multiple drug targets in a highly parallel fashion. The proposed assay methodology has recently been demonstrated using kinases as a model system, and a patent has been filed to protect the assay method. However, there is a critical need to further develop this technology to reach the stage where commercialization is possible. The I2I grant will allow us to achieve the following objectives to achieve this goal:
1) Optimization of staining/destaining methods; 2) further expanding the number of kinases and evaluation of unconventional kinases with a range of substrate types to validate generality and show key areas where this technology can outperform conventional kinase assays; 3) evaluating array robustness, reproducibility, storage stability for several kinases; 4) integration of the microarray technology into an HTS environment (MacHTS) for critical beta-testing of the array platform as a tool for rapid, nanovolume screening and; 5) third party evaluation and validation. The successful completion of these objectives will provide us with the key validation data needed to spin-out a new company in the drug discovery area. The new products and screening services offered by the company will be critical for the development of new pharmaceuticals and biotechnology products.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
370932-2008
Name nom
Brennan, John
Department département
Chemistry
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
125000
Program id
I2IPJ
Program nane en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
Optimization and validation of a sol-gel based microarray platform for high-throughput screening
Keyword
NA
Application summary
An emerging method for performing bioassays is to print hundreds or even thousands of different proteins on a single microscope slide as micron-sized spots in an ordered pattern (a microarray), and to then expose the proteins to an analyte solution that can simultaneously react with several proteins on the array. Proteins that react with the analyte solution can then be stained with a fluorescent dye, and a pattern of response from the array can be visualized to determine the biological activity of the analytes. Over the past 3 years our group has been developing a new type of protein microarray that is based on the entrapment of proteins into a silica-based polymer, which is then printed as an array. This has allowed us to develop a highly parallel fluorescence-based small molecule screening technology for simultaneous assaying of multiple drug targets in a highly parallel fashion. The proposed assay methodology has recently been demonstrated using kinases as a model system, and a patent has been filed to protect the assay method. However, there is a critical need to further develop this technology to reach the stage where commercialization is possible. The I2I grant will allow us to achieve the following objectives to achieve this goal:
1) Optimization of staining/destaining methods; 2) further expanding the number of kinases and evaluation of unconventional kinases with a range of substrate types to validate generality and show key areas where this technology can outperform conventional kinase assays; 3) evaluating array robustness, reproducibility, storage stability for several kinases; 4) integration of the microarray technology into an HTS environment (MacHTS) for critical beta-testing of the array platform as a tool for rapid, nanovolume screening and; 5) third party evaluation and validation. The successful completion of these objectives will provide us with the key validation data needed to spin-out a new company in the drug discovery area. The new products and screening services offered by the company will be critical for the development of new pharmaceuticals and biotechnology products.